MX2010000368A - Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos. - Google Patents
Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos.Info
- Publication number
- MX2010000368A MX2010000368A MX2010000368A MX2010000368A MX2010000368A MX 2010000368 A MX2010000368 A MX 2010000368A MX 2010000368 A MX2010000368 A MX 2010000368A MX 2010000368 A MX2010000368 A MX 2010000368A MX 2010000368 A MX2010000368 A MX 2010000368A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- modifying
- amyloid beta
- peptidic compounds
- beta oligomers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a métodos para inhibir, regular y/o modular la formación de oligómeros ß1-42 amiloides neurotóxicos, no fibrilares, globulares, solubles, a partir de monómeros ß1-42 amiloides. También se describen métodos para tratar un paciente que sufre de enfermedades asociadas con la formación de oligómeros ß1-42 amiloides neurotóxicos, no fibrilares, globulares, solubles.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/073408 WO2009008890A1 (en) | 2007-07-12 | 2007-07-12 | METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010000368A true MX2010000368A (es) | 2010-07-02 |
Family
ID=39205308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010000368A MX2010000368A (es) | 2007-07-12 | 2007-07-12 | Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2170322B1 (es) |
CA (1) | CA2692773A1 (es) |
ES (1) | ES2401664T3 (es) |
MX (1) | MX2010000368A (es) |
WO (1) | WO2009008890A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8962677B2 (en) | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
US9006283B2 (en) | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
WO2009079566A2 (en) | 2007-12-18 | 2009-06-25 | Acumen Pharmaceuticals, Inc. | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US20100029773A1 (en) * | 2004-05-24 | 2010-02-04 | Ludwig-Maximilians-Universitat Munchen | Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift) |
CA2652449A1 (en) * | 2006-05-19 | 2007-11-29 | Waratah Pharmaceuticals Inc. | Screening methods for amyloid beta modulators |
-
2007
- 2007-07-12 MX MX2010000368A patent/MX2010000368A/es active IP Right Grant
- 2007-07-12 EP EP07840403A patent/EP2170322B1/en active Active
- 2007-07-12 ES ES07840403T patent/ES2401664T3/es active Active
- 2007-07-12 CA CA 2692773 patent/CA2692773A1/en not_active Abandoned
- 2007-07-12 WO PCT/US2007/073408 patent/WO2009008890A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2170322A1 (en) | 2010-04-07 |
ES2401664T3 (es) | 2013-04-23 |
CA2692773A1 (en) | 2009-01-15 |
WO2009008890A1 (en) | 2009-01-15 |
EP2170322B1 (en) | 2013-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010000368A (es) | Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos. | |
WO2009009768A3 (en) | METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS | |
WO2010021693A3 (en) | Mif modulators | |
UA98629C2 (ru) | Соединения и способ модуляции киназ | |
MX2011013739A (es) | Composiciones y metodos para reducir trigliceridos sin elevar los niveles de ldl-c en un sujeto en terapia de estatina concomitante. | |
WO2011140202A3 (en) | Mif modulators | |
EP2294184A4 (en) | TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY | |
WO2007126765A3 (en) | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | |
MY156243A (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
WO2008091692A3 (en) | Methods of diagnosing, treating, and preventing increased vascular permeability | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
WO2010068710A3 (en) | Kinase inhibitor compounds | |
WO2009044173A3 (en) | Methods of treating cancer using notch pathway inhibitors | |
WO2009124330A3 (de) | Behandlung von tumorerkrankungen | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
TN2010000155A1 (en) | Organic compounds | |
WO2011025862A3 (en) | Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1 | |
WO2019166412A9 (en) | Modulation of pla2-g1b in therapy | |
AU2016204334A1 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | |
WO2019169333A8 (en) | Afibrotic compounds, devices, and uses thereof | |
AU2010279892A8 (en) | Humanized anti-amyloid-b oligomer antibody | |
WO2008118792A3 (en) | Gamma delta t cells and methods of treatment of interleukin-17 related conditions | |
WO2006078336A3 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |